Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program

被引：0
|
作者：
Xin Du
Jie Jin
Zhen Cai
Fangping Chen
Dao-bin Zhou
Li Yu
Xiaoyan Ke
Xiao Li
Depei Wu
Fanyi Meng
Dena DeMarco
Jingshan Zhang
Jay Mei
Jian Hou
机构：
[1] Guangdong General Hospital,The 1st Affiliated Hospital
[2] Zhejiang University,Department of Hematology
[3] Xiangya Hospital of Central South University,undefined
[4] Peking Union Medical College Hospital,undefined
[5] The 301 Hospital-Chinese PLA General Hospital,undefined
[6] Peking University Third Hospital,undefined
[7] Shanghai 6th Hospital,undefined
[8] The 1st Affiliated Hospital of Soochow University,undefined
[9] Nanfang Hospital of Southern Medicine University in Guangzhou,undefined
[10] Celgene Corporation,undefined
[11] Shanghai Changzheng Hospital,undefined
来源：
BMC Cancer | / 16卷
关键词：
Relapsed/refractory multiple myeloma; Chinese patients; Lenalidomide; Low-dose dexamethasone; Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Long-term use of lenalidomide and low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: MM-024 Extended Access Program
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    DeMarco, Dena
    Zhang, Jingshan
    Mei, Jay
    Hou, Jian
    BMC CANCER, 2016, 16
  • [2] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Dao-bin Zhou
    Li Yu
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Dena DeMarco
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Jian Hou
    International Journal of Hematology, 2015, 101 : 569 - 577
  • [3] Lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma and renal impairment
    Zhou, Dao-bin
    Yu, Li
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    DeMarco, Dena
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    Hou, Jian
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 569 - 577
  • [4] Low-dose lenalidomide and dexamethasone combination treatment in elderly patients with relapsed and refractory multiple myeloma
    Wang, Chunling
    He, Zhengmei
    Shi, Yuye
    Zhang, Lijuan
    Chen, Yue
    Chen, Zhi
    Yu, Liang
    HEMATOLOGY, 2017, 22 (02) : 88 - 92
  • [5] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Jian Hou
    Xin Du
    Jie Jin
    Zhen Cai
    Fangping Chen
    Dao-bin Zhou
    Li Yu
    Xiaoyan Ke
    Xiao Li
    Depei Wu
    Fanyi Meng
    Huisheng Ai
    Jingshan Zhang
    Honeylet Wortman-Vayn
    Nianhang Chen
    Jay Mei
    Jianmin Wang
    Journal of Hematology & Oncology, 6
  • [6] A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial
    Hou, Jian
    Du, Xin
    Jin, Jie
    Cai, Zhen
    Chen, Fangping
    Zhou, Dao-bin
    Yu, Li
    Ke, Xiaoyan
    Li, Xiao
    Wu, Depei
    Meng, Fanyi
    Ai, Huisheng
    Zhang, Jingshan
    Wortman-Vayn, Honeylet
    Chen, Nianhang
    Mei, Jay
    Wang, Jianmin
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [7] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
    Kobayashi, Tsutomu
    Kuroda, Junya
    Fuchida, Shin-ichi
    Kaneko, Hitomi
    Yagi, Hideo
    Shibayama, Hirohiko
    Tanaka, Hirokazu
    Kosugi, Satoru
    Uoshima, Nobuhiko
    Kobayashi, Masayuki
    Adachi, Yoko
    Ohta, Kensuke
    Ishii, Kazuyoshi
    Uchiyama, Hitoji
    Matsuda, Mitsuhiro
    Nakatani, Eiji
    Tsudo, Mitsuru
    Shimazaki, Chihiro
    Takaori-Kondo, Akifumi
    Nomura, Shosaku
    Matsumura, Itaru
    Taniwaki, Masafumi
    Kanakura, Yuzuru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (01) : 37 - 45
  • [8] Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma
    Tsutomu Kobayashi
    Junya Kuroda
    Shin-ichi Fuchida
    Hitomi Kaneko
    Hideo Yagi
    Hirohiko Shibayama
    Hirokazu Tanaka
    Satoru Kosugi
    Nobuhiko Uoshima
    Masayuki Kobayashi
    Yoko Adachi
    Kensuke Ohta
    Kazuyoshi Ishii
    Hitoji Uchiyama
    Mitsuhiro Matsuda
    Eiji Nakatani
    Mitsuru Tsudo
    Chihiro Shimazaki
    Akifumi Takaori-Kondo
    Shosaku Nomura
    Itaru Matsumura
    Masafumi Taniwaki
    Yuzuru Kanakura
    International Journal of Hematology, 2015, 101 : 37 - 45
  • [9] Addition of clarithromycin to lenalidomide/low-dose dexamethasone was effective in a case of relapsed myeloma after long-term use of lenalidomide
    Hiroki Kato
    Yasushi Onishi
    Yoko Okitsu
    Yuna Katsuoka
    Tohru Fujiwara
    Noriko Fukuhara
    Kenichi Ishizawa
    Masanori Takagawa
    Hideo Harigae
    Annals of Hematology, 2013, 92 : 1711 - 1712
  • [10] Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma
    Seok Jin Kim
    Danbee Kang
    Yong Park
    Yeung-Chul Mun
    Kihyun Kim
    Jin Seok Kim
    Chang-Ki Min
    Juhee Cho
    Supportive Care in Cancer, 2021, 29 : 4969 - 4977
12345